EICHOR
● Recruiting
An Imaging Study of Anti-GD2-800CW in Patients With Neuroblastoma
Condition: Neuroblastoma · Sponsor: Princess Maxima Center for Pediatric Oncology
About this study
This is a non-randomized, open label phase Ib/II dose-escalation and expansion study designed to define the recommended dose of anti-GD2-800CW in pediatric neuroblastoma patients. The aim of this imaging study is to determine a safe and effective dose of anti-GD2-800CW for intra-operative detection of neuroblastoma using NIR fluorescence.
This description comes directly from the study's public registry record.
Talk to the study team
Marieke Kietselaer · +31 88 972 7272 · trialmanagement@prinsesmaximacentrum.nl
Always discuss trial participation with your own doctor first.
Locations (1)
| Prinses Maxima Centrum | Utrecht, Netherlands | Recruiting |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07399821